Clinical Trial Update: Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma [Phase 3]

View source ↗

Summary

Soquelitinib is being studied in a Phase 3 trial versus standard of care for relapsed/refractory peripheral T-cell lymphomas, including PTCL-NOS, AITL, and TFH-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma
• Follicular Helper T-cell Lymphoma
• Nodal Peripheral T-cell Lymphoma with Tfh Phenotype
• Peripheral T-cell Lymphoma Not Otherwise Specified
• Systemic Anaplastic Large Cell Lymphoma

Drugs mentioned

• Soquelitinib

Snippet

Sponsor: Corvus Pharmaceuticals, Inc. | Conditions: Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma | Phase 3 | Status: RECRUITING